THPTA ligand

Cat. #	Quantity	Price	Lead time
F4050	100 mg	$65	in stock
H4050	500 mg	$199	in stock
I4050	1 g	$369	in stock
K4050	5 g	$1568	in stock

Bulk inquiry

Found better price? Let us know and we will propose the way forward!

THPTA ligand (tris-hydroxypropyltriazolylmethylamine) is a triazole ligand for water-based copper-catalyzed click chemistry reactions. This reagent is very well water-soluble. It is especially useful for click chemistry labeling and conjugation of proteins, including antibodies, when organic co-solvents are undesirable.

Download in
ChemDraw format

Customers also purchased with this product

AF 488 NHS ester

AF 488 NHS ester, a bright, photostable, and hydrophilic fluorescent dye for the green channel.

sulfo-Cyanine3 tetrazine

Water soluble sulfo-Cyanine3 dye tetrazine derivative for TCO ligation labeling with trans-cyclooctenes.

BDP TR-X-NHS ester

BDP TR-X-NHS ester is a derivative of BDP TR containing a long linker based on aminohexanoic acid (C6). The dye has absorption and emission close to ROX. The NHS ester function can be used to conjugate proteins and peptides.

General properties

Appearance:	off white solid
Molecular weight:	434.5
CAS number:	760952-88-3
Molecular formula:	C₁₈H₃₀N₁₀O₃
IUPAC name:	3-[4-[[bis[[1-(3-hydroxypropyl)triazol-4-yl]methyl]amino]methyl]triazol-1-yl]propan-1-ol
Solubility:	good in water, DMF, DMSO
Quality control:	NMR ¹H, HPLC-MS (95%)
Storage conditions:	Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks.
MSDS:	Download
	Product specifications

Product citations

Cardenas, A.J.; Thomas, K.S.; Broden, M.W.; Ferraro, N.J.; John, C.M.; Pires, M.M.; Jarvis, G.A.; Criss, A.K. Neisseria gonorrhoeaescavenges host sialic acid for Siglec-mediated, complement-independent suppression of neutrophil activation. bioRxiv, 2024, preprint. doi: 10.1101/2024.01.17.576097
Slapak, E.J.; el Mandili, M.; Ten Brink, M.S.; Kros, A.; Bijlsma, M.F.; Spek, C.A. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. Cancer Letters, 2024, 590, 216845. doi: 10.1016/j.canlet.2024.216845
Narum, S.; Deal, B.; Ogasawara, H.; Mancuso, J. N.; Zhang, J.; Salaita, K. An Endosomal Escape Trojan Horse Platform to Improve Cytosolic Delivery of Nucleic Acids. ACS Nano, 2024, 18(8), 6186–6201. doi: 10.1021/acsnano.3c09027
Slapak, E.J.; el Mandili, M.; Brink, M.S.T.; Kros, A.; Bijlsma, M.F.; Spek, C.A. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer. International Journal of Molecular Sciences, 2023, 24(13), 10704. doi: 10.3390/ijms241310704